Literature DB >> 21707759

Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement.

Pia Moinzadeh, Thomas Krieg, Martin Hellmich, Jürgen Brinckmann, Elena Neumann, Ulf Müller-Ladner, Alexander Kreuter, Daniel Dumitrescu, Stephan Rosenkranz, Nicolas Hunzelmann.   

Abstract

BACKGROUND: Fibrosis is characterized by an excessive accumulation of connective tissue because of an imbalance between synthesis and degradation of extracellular matrix proteins. Systemic sclerosis (SSc) is a prototypic chronic inflammatory disease leading to a severe fibrosis of the skin and many internal organs. QUESTIONS ADDRESSED: We investigated whether serum MMP-7 levels reflect the activity of the fibrotic reaction in systemic sclerosis. EXPERIMENTAL
DESIGN: Serum samples were obtained from 123 patients with systemic sclerosis. MMP-serum levels of all patients with SSc were compared with age-matched healthy controls.
RESULTS: Significantly increased median serum MMP-7 levels were found in patients with SSc when compared with controls. The median MMP-7 serum level of patients with lung fibrosis (LF) was significantly higher compared with those without LF. Accordingly, patients with dyspnea and DLCO (diffusion capacity of the lung for carbon monoxide) levels below 60% showed significantly higher median MMP-7 levels.
CONCLUSIONS: Elevated MMP-7 levels are associated with an advanced stage of SSc and LF. These data suggest that in SSc MMP-7 is involved in the process of fibrotic tissue remodelling.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707759     DOI: 10.1111/j.1600-0625.2011.01321.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  21 in total

Review 1.  Matrix metalloproteinases: a review of their structure and role in systemic sclerosis.

Authors:  Wen-jia Peng; Jun-wei Yan; Ya-nan Wan; Bing-xiang Wang; Jin-hui Tao; Guo-jun Yang; Hai-feng Pan; Jing Wang
Journal:  J Clin Immunol       Date:  2012-07-06       Impact factor: 8.317

Review 2.  Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!

Authors:  Jelena Čolić; Marco Matucci Cerinic; Serena Guiducci; Nemanja Damjanov
Journal:  J Scleroderma Relat Disord       Date:  2019-06-28

Review 3.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

4.  Dysregulation of upstream and downstream transforming growth factor-β transcripts in livers of children with biliary atresia and fibrogenic gene signatures.

Authors:  Tatiana Iordanskaia; Monica J Hubal; Emily Koeck; Christopher Rossi; Kathleen Schwarz; Evan P Nadler
Journal:  J Pediatr Surg       Date:  2013-10       Impact factor: 2.545

Review 5.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

6.  Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers.

Authors:  P Jacquerie; M Henket; B André; C Moermans; D de Seny; F Gester; R Louis; M Malaise; J Guiot
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

7.  Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Hilary F Armstrong; Anna J Podolanczuk; R Graham Barr; Elizabeth C Oelsner; Steven M Kawut; Eric A Hoffman; Russell Tracy; Naftali Kaminski; Robyn L McClelland; David J Lederer
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 30.528

Review 8.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

9.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03

Review 10.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.